Almonertinib-induced interstitial lung disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Almonertinib-induced interstitial lung disease

Published:2021-01-22 Issue:3 Volume:100 Page:e24393
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Jiang Ting,Luo Yiyang,Wang Binbin

Funder

Zhejiang Provincial Project for the key discipline of traditional Chinese Medicine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference23 articles.

1. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer;Hatami;Eur J Pharmacol,2020

2. - Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small;Sg;Mol Cancer,2018

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

5. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The influence of drug-induced metabolic enzyme activity inhibition and CYP3A4 gene polymorphism on aumolertinib metabolism;Frontiers in Pharmacology;2024-05-24

2. Aumolertinib: effective treatment for asymptomatic pulmonary giant cell carcinoma with EGFR L858R mutation - a case report;Frontiers in Oncology;2023-11-27

3. Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality;BMC Pulmonary Medicine;2023-03-08

4. Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling;Molecules;2023-01-17

5. Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review;Anti-Cancer Drugs;2022-11-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3